Brivoligide - Adynxx

Drug Profile

Brivoligide - Adynxx

Alternative Names: AYX-1; Brivoligide-sodium

Latest Information Update: 16 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adynxx
  • Class Analgesics; Oligonucleotides
  • Mechanism of Action Early growth response protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain; Postoperative pain

Most Recent Events

  • 12 Apr 2018 Efficacy and adverse events data from a phase II trial in Pain released by Adynxx
  • 19 Dec 2017 Adynxx completes a phase II trial for Postoperative and Chronic pain (Prevention) in USA (Intrathecal) (NCT02807428)
  • 04 Oct 2017 Adynxx comples enrolment in a phase II trial for Postoperative and Chronic pain (Prevention) in USA (Intrathecal) (NCT02807428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top